Miniatura

Fitxers

jem_20220258.pdf (4 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-11-07

Llicència de publicació

cc-by (c) Sokal, Aurélien et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/224137

Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1084/jem.20220258

Resum

Intact B cell responses to SARS-CoV-2 mRNA vaccines in patients with genetic or acquired type I IFN deficiencies suggest that type I IFNs induced by mRNA vaccines are not required for vaccine efficacy. Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination in SARS-CoV-2 naive patients with inherited TLR7, IRF7, or IFNAR1 deficiency, as well as young patients with autoantibodies neutralizing type I IFNs due to autoimmune polyendocrine syndrome type-1 (APS-1) and older individuals with age-associated autoantibodies to type I IFNs. The receptor-binding domain spike protein (RBD)-specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors. Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes. The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients. These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines.

Matèries

Immunoregulació, Betacoronavirus, Antígens

Matèries (anglès)

Immunoregulation, Betacoronavirus, Antigens

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SOKAL, Aurélien, BASTARD, Paul, CHAPPERT, Pascal, BARBA SPAETH, Giovanna, FOURATI, Slim, VANDERBERGHE, Alexis, LAGOUGE ROUSSEY, Pauline, MEYTS, Isabelle, GERVAIS, Adrian, BOUVIER ALIAS, Magali, AZZAOUI, Imane, FERNÁNDEZ, Ignacio, LA SELLE, Andréa de, ZHANG, Qian, BIZIEN, Lucy, PELLIER, Isabelle, LINGLART, Agnès, ROTHENBUHLER, Anya, MARCOUX, Estelle, ANXIONNAT, Raphael, CHEIKH, Nathalie, LÉGER, Juliane, AMADOR BORRERO, Blanca, FOUYSSAC, Fanny, MENUT, Vanessa, GOFFARD, Jean christophe, STOREY, Caroline, DEMILY, Caroline, MALLEBRANCHE, Coralie, TROYA, Jesus, PUJOL, Aurora, ZINS, Marie, TIBERGHIEN, Pierre, GRAY, Paul e., MCNAUGHTON, Peter, SULLIVAN, Anna, PEAKE, Jane, LEVY, Romain, LANGUILLE, Laetitia, RODIGUEZ GALLEGO, Carlos, BOISSON, Bertrand, GALLIEN, Sébastien, NEVEN, Bénédicte, MICHEL, Marc, GODEAU, Bertrand, ABEL, Laurent, REY, Felix a., WEILL, Jean claude, REYNAUD, Claude agnès, TANGYE, Stuart g., CASANOVA, Jean laurent, MAHÉVAS, Matthieu. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination. _The Journal of Experimental Medicine_. 2022. Vol. 220, núm. 1, pàgs. e20220258. [consulta: 20 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/224137]

Exportar metadades

JSON - METS

Compartir registre